QUANTRO Therapeutics GmbH is a privately funded research company that specializes in discovering and developing innovative therapeutics for cancer and other diseases. By utilizing functional-genetics and transcriptomics technologies, QUANTRO aims to revolutionize cancer drug discovery by creating a precise and extensive pipeline for cell-based compound screens. With a focus on interfering with disease-causing transcriptional programs, QUANTRO uses proprietary transcriptional signatures to identify drug candidates that target transcriptional regulators.

This unique approach, known as 'transcriptional fingerprinting,' allows QUANTRO to expand the scope of pharmacologic interventions in various cellular, target, and disease contexts. QUANTRO Therapeutics GmbH was founded in Vienna, Austria, as a spin-off of the Research Institute of Molecular Pathology (IMP) and the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA). The company benefits from its location at the Vienna BioCenter, one of Europe's leading life-science hubs.

With support from investors such as Boehringer Ingelheim Venture Fund and Evotec, QUANTRO has the expertise and resources to drive groundbreaking advancements in mRNA sequencing-based drug discovery. Their goal is to unlock previously 'undruggable' targets, leading to novel therapeutic modalities that can transform patient care. Learn more about QUANTRO Therapeutics GmbH and their pioneering work at www.

quantro-tx. com